Tumour-derived SAA1 reprogrammes macrophages to promote CXCL1-mediated metastasis in Ovarian Cancer

Abstract

Key points:

Keywords

CXCL1 / macrophage / metastasis / ovarian cancer / SAA1 / tumour microenvironment

References

[1] Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11): 668-679.

[2] Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019; 393(10177): 1240-1253.

[3] Bayraktar E, Chen S, Corvigno S, Liu J, Sood AK. Ovarian cancer metastasis: looking beyond the surface. Cancer Cell. 2024; 42(10): 1631-1636.

[4] Caruso G, Weroha SJ, Cliby W. Ovarian Cancer: a Review. JAMA, J Am Med Assoc. 2025; 334(14): 1278-1291.

[5] Dogra S, Adhikari L, Benbrook DM, et al. Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics. Mol Cancer. 2025; 24(1): 257.

[6] Wang Y, Zhu N, Liu J, et al. Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements. J Transl Med. 2025; 23(1): 539.

[7] Nougaret S, Sadowski E, Lakhman Y, et al. The BUMPy road of peritoneal metastases in ovarian cancer. Diagn Intervent Imag. 2022; 103(10): 448-459.

[8] Lian XY, Zhang H, Liu Q, et al. Ovarian cancer-excreted exosomal miR-199a-5p suppresses tumor metastasis by targeting hypoxia-inducible factor-2α in hypoxia microenvironment. Can Commun (London, England). 2020; 40(8): 380-385.

[9] Samardzija C, Luwor RB, Volchek M, Quinn MA, Findlay JK, Ahmed N. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. Mol Cancer. 2015; 14: 152.

[10] Kinker GS, Greenwald AC, Tal R, et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat Genet. 2020; 52(11): 1208-1218.

[11] de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3): 374-403.

[12] Mantovani A, Marchesi F, Di Mitri D, Garlanda C. Macrophage diversity in cancer dissemination and metastasis. Cell Mol Immunol. 2024; 21(11): 1201-1214.

[13] Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer. 2015; 3: 7.

[14] Nasir I, McGuinness C, Poh AR, Ernst M, Darcy PK, Britt KL. Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies. Trends Immunol. 2023; 44(12): 971-985.

[15] Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023; 186(8): 1627-1651.

[16] Zhao C, Zeng N, Zhou X, et al. CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3. BMC Cancer. 2023; 23(1): 392.

[17] Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475(7355): 222-225.

[18] Jafari R, Almqvist H, Axelsson H, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014; 9(9): 2100-2122.

[19] Kopper O, de Witte CJ, Lõhmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019; 25(5): 838-849.

[20] Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002; 2(9): 664-674.

[21] Etzerodt A, Moulin M, Doktor TK, et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med. 2020; 217(4).

[22] Hornburg M, Desbois M, Lu S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021; 39(7): 928-944.e6.

[23] Zheng X, Wang X, Cheng X, et al. Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat Can. 2023; 4(8): 1138-1156.

[24] Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discovery. 2022; 21(11): 799-820.

[25] Blériot C, Dunsmore G, Alonso-Curbelo D, Ginhoux F. A temporal perspective for tumor-associated macrophage identities and functions. Cancer Cell. 2024; 42(5): 747-758.

[26] El-Arabey AA, Alkhalil SS, Al-Shouli ST, et al. Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction. Med Oncol (Northwood, London, England). 2023; 40(5): 142.

[27] Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2001; 60(2): 124-127.

[28] Lee JY, Hall JA, Kroehling L, et al. Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease. Cell. 2020; 183(7): 2036-2039.

[29] Wang H, Wang S, Lei Y, et al. Serum amyloid A1-induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression. Hepatol (Baltimore, Md). 2025;

[30] Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut. 2008; 57(10): 1398-1405.

[31] Niu X, Yin L, Yang X, et al. Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer. Cancer Sci. 2022; 113(4): 1140-1153.

[32] Wang X, Wen S, Du X, et al. SAA suppresses α-PD-1 induced anti-tumor immunity by driving T(H)2 polarization in lung adenocarcinoma. Cell Death Dis. 2023; 14(11): 718.

[33] Yu MH, Li X, Li Q, et al. SAA1 increases NOX4/ROS production to promote LPS-induced inflammation in vascular smooth muscle cells through activating p38MAPK/NF-κB pathway. BMC Mole Cell Biol. 2019; 20(1): 15.

[34] Hu H, Yang M, Huang B, et al. Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1-IL-1β axis. J Exp Clin Cancer Res. 2025; 44(1): 277.

[35] Su SB, Gong W, Gao JL, et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999; 189(2): 395-402.

[36] Liu X, Song Y, Hu S, et al. Serum amyloid A contributes to radiation-induced lung injury by activating macrophages through FPR2/Rac1/NF-κB pathway. Int J Biol Sci. 2024; 20(12): 4941-4956.

[37] Li B, Dong Z, Liu H, et al. Serum amyloid A stimulates lipoprotein-associated phospholipase A2 expression in vitro and in vivo. Atherosclerosis. 2013; 228(2): 370-379.

[38] Xu X, Gao W, Li L, et al. Annexin A1 protects against cerebral ischemia-reperfusion injury by modulating microglia/macrophage polarization via FPR2/ALX-dependent AMPK-mTOR pathway. J Neuroinflam. 2021; 18(1): 119.

[39] He F, Tay AHM, Calandigary A, et al. FPR2 shapes an immune-excluded pancreatic tumor microenvironment and drives T-cell exhaustion in a sex-dependent manner. Cancer Res. 2023; 83(10): 1628-1645.

[40] Liang W, Chen K, Gong W, et al. The contribution of chemoattractant GPCRs, formylpeptide receptors, to inflammation and cancer. Front Endocrinol. 2020; 11: 17.

[41] Lee C, Han J, Jung Y. Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver. Exp Mol Med. 2023; 55(2): 325-332.

[42] Ge YJ, Liao QW, Xu YC, Zhao Q, Wu BL, Ye RD. Anti-inflammatory signaling through G protein-coupled receptors. Acta Pharmacol Sin. 2020; 41(12): 1531-1538.

[43] Senga T, Iwamoto S, Yoshida T, et al. LSSIG is a novel murine leukocyte-specific GPCR that is induced by the activation of STAT3. Blood. 2003; 101(3): 1185-1187.

[44] Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122(3): 787-795.

[45] Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011; 11(11): 723-737.

[46] Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150(1): 165-178.

[47] Zhang W, Peng Y, Zhou M, et al. RBM14 enhances transcriptional activity of p23 regulating CXCL1 expression to induce lung cancer metastasis. Acta Pharm Sin B. 2025; 15(6): 3059-3072.

[48] Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochimica et biophysica acta Reviews on cancer. 2019; 1871(2): 289-312.

[49] Lazennec G, Rajarathnam K, Richmond A. CXCR2 chemokine receptor—a master regulator in cancer and physiology. Trends Mol Med. 2024; 30(1): 37-55.

[50] Wang N, Liu W, Zheng Y, et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling. Cell Death Dis. 2018; 9(9): 880.

[51] Pecot CV, Rupaimoole R, Yang D, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4: 2427.

[52] Horn LA, Lind H, Fousek K, et al. Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models. J Exp Clin Cancer Res. 2024; 43(1): 318.

[53] Cheng Y, Mo F, Li Q, et al. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. Mol Cancer. 2021; 20(1): 62.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.